contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


magle-chemoswed-holding-reports-financial-results-for-third-quarter-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Magle Chemoswed Holding

Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.Q3 2025 KEY INDICATORSNet Sales amounted to 71.5 MSEK (64.6)EBITDA equaled 33.4 MSEK (26....

<div class="mfn-preamble"><p><strong>Magle Group announces its Q3 2025 results, marked by clear progress across key areas of the business.</strong></p></div><div class="mfn-body"><p><strong>Q3 2025 KEY INDICATORS</strong></p><ul><li>Net Sales amounted to 71.5 MSEK (64.6)</li><li>EBITDA equaled 33.4 MSEK (26.5)</li><li>Operating profit (EBIT) is 20.3 MSEK (13.8)</li><li>Earnings per share SEK 0.15 (0.89) per share</li></ul><p>“The third quarter delivered a stabilised and more aligned performance across the Group, following a challenging Q2. We saw a strong performance from Magle Chemoswed, supported by operational flexibility and sustained demand from Magle Biopolymers. Magle Pharmacept also made solid strategic strides, including international expansion for SmartPAN® and EmboCept® S. While Magle Biopharma continues to face market-driven headwinds, our internal cell therapy development remains a longer-term focus. We are progressing well with our integration and restructuring agenda and remain focused on completing systems alignment and unlocking synergies.” – Justin Pierce, CEO</p></div><div class="mfn-footer mfn-contacts mfn-c123be755a9c"><p><strong class="mfn-heading-1">Contacts Justin &amp; Aaron</strong></p><hr><p>Justin Pierce, CEO, phone +46 (0)70 593 58 21,&nbsp;<a rel="noopener" href="mailto:justin.pierce@maglechemoswed.com">justin.pierce@maglechemoswed.com</a></p><p>Aaron Wong, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com</p></div><div class="mfn-footer mfn-about mfn-70935ab259f1"><p><strong class="mfn-heading-1">About Us</strong></p><hr><p>The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on&nbsp;<strong><a rel="noopener" href="http://www.maglechemoswed.com/">www.maglechemoswed.com</a></strong> and <strong><a rel="noopener" href="https://maglegroup.com/">www.maglegroup.com</a></strong><strong> </strong>and <strong><a rel="noopener" href="http://www.maglepharmacept.com">www.maglepharmacept.com</a></strong><strong> </strong>and <strong><a rel="noopener" href="https://maglebiopolymers.com/">www.maglebiopolymers.com</a></strong></p><p>Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at <a rel="noopener" href="mailto:ca@vatorsec.se">ca@vatorsec.se</a> or +46 (0)8-580 065 99.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-11-14 08:30 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/7682796f-5ef3-4b5b-88d0-61fb9764b57c/magle-group-q3-interim-report-final.pdf" class="mfn-primary">Magle Group Q3 Interim Report Final</a></p></div>